# To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV

> **NCT00346892** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 450 (—)

## Conditions studied

- Rotavirus Infections

## Interventions

- **BIOLOGICAL:** Rotavirus (vaccine)

## Key facts

- **NCT ID:** NCT00346892
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2003-03
- **Final completion:** —
- **Target enrollment:** 450 (—)
- **Last updated:** 2016-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346892, "To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00346892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*